C4 Therapeutics Q2 EPS $(0.37) Beats $(0.41) Estimate, Sales $6.463M Beat $5.240M Estimate
Benzinga Newsdesk 1 year ago
EarningsEarnings BeatsNews
C4 Therapeutics (NASDAQ:CCCC) reported quarterly losses of $(0.37) per share which beat the analyst consensus estimate of $(0.41) by 9.76 percent. This is a 42.31 percent decrease over losses of $(0.26) per share from
C4 Therapeutics (NASDAQ:CCCC) reported quarterly losses of $(0.37) per share which beat the analyst consensus estimate of $(0.41) by 9.76 percent. This is a 42.31 percent decrease over losses of $(0.26) per share from the same period last year. The company reported quarterly sales of $6.463 million which beat the analyst consensus estimate of $5.240 million by 23.34 percent. This is a 46.17 percent decrease over sales of $12.006 million the same period last year.